January 12, 2017
(STAT News) – In the Obama administration’s final days, the National Cancer Institute is establishing an ambitious new program designed to allow scientists to more quickly access new drugs and compounds for novel research. One of the last achievements of Vice President Joe Biden’s cancer moonshot initiative before he leaves office, the program was unveiled Wednesday and will begin as an agreement between the institute and six drug companies. The hope is that the arrangement, in which NCI will act as an intermediary between outside researchers and drug makers, will make it easier for scientists to pursue new combination therapies for cancer, which are widely seen as one of the most promising avenues for better cancer treatment.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.